The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy
Abstract
The α‐gal epitope (Galα1‐3Galβ1‐(3)4GlcNAc‐R) is abundantly synthesized on glycolipids and glycoproteins of non‐primate mammals and New World monkeys by the glycosylation enzyme α1,3galactosyltransferase (α1,3GT). In humans, apes and Old World monkeys, this epitope is absent because the α1,3GT gene was inactivated in ancestral Old World primates. Instead, humans, apes and Old World monkeys produce the anti‐Gal antibody, which specifically interacts with α‐gal epitopes and which constitutes ∼1% of circulating immunoglobulins. Anti‐Gal has functioned as an immunological barrier, preventing the transplantation of pig organs into humans, because anti‐Gal binds to the α‐gal epitopes expressed on pig cells. The recent generation of α1,3GT knockout pigs that lack α‐gal epitopes has resulted in the elimination of this immunological barrier. Anti‐Gal can be exploited for clinical use in cancer immunotherapy by targeting autologous tumour vaccines to APC, thereby increasing their immunogenicity. Autologous intact tumour cells from haematological malignancies, or autologous tumour cell membranes from solid tumours are processed to express α‐gal epitopes by incubation with neuraminidase, recombinant α1,3GT and with uridine diphosphate galactose. Subsequent immunization with such autologous tumour vaccines results in in vivo opsonization by anti‐Gal IgG binding to these α‐gal epitopes. The interaction of the Fc portion of the vaccine‐bound anti‐Gal with Fcγ receptors of APC induces effective uptake of the vaccinating tumour cell membranes by the APC, followed by effective transport of the vaccinating tumour membranes to the regional lymph nodes, and processing and presentation of the tumour‐associated antigen (TAA) peptides. Activation of tumour‐specific T cells within the lymph nodes by autologous TAA peptides may elicit an immune response that in some patients will be potent enough to eradicate the residual tumour cells that remain after completion of standard therapy. A similar expression of α‐gal epitopes can be achieved by transduction of tumour cells with an adenovirus vector (or other vectors) containing the α1,3GT gene, thus enabling anti‐Gal‐mediated targeting of the vaccinating transduced cells to APC. Intratumoral delivery of the α1,3GT gene by various vectors results in the expression of α‐gal epitopes. Such expression of the xenograft carbohydrate phenotype is likely to induce anti‐Gal‐mediated destruction of the tumour lesion, similar to rejection of xenografts by this antibody. Opsonization of the destroyed tumour cell membranes by anti‐Gal IgG further targets them to APC, thus converting the tumour lesion, treated by the α1,3GT gene, into an in situ autologous tumour vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Production of α-1,3-Galactosyltransferase Knockout Pigs by Nuclear Transfer Cloning
Lai, L., Kolber-Simonds, D., Park, K.-W., Cheong, H.-T., Greenstein, J. L., Im, G.-S., Samuel, M., Bonk, A., Rieke, A., Day, B. N., et al. (2002) · Science · doi:10.1126/science.1068228 · Cited by 1,334
Production of α1,3-Galactosyltransferase-Deficient Pigs
Phelps, C. J., Koike, C., Vaught, T. D., Boone, J., Wells, K. D., Chen, S.-H., Ball, S., Specht, S. M., Polejaeva, I. A., Monahan, J. A., et al. (2003) · Science · doi:10.1126/science.1078942 · Cited by 1,112
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Théry, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.371 · Cited by 898
Determination of aminosugar linkages in glycolipids by methylation
Stellner, K., Saito, H., & Hakomori, S.-I. (1973) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(73)90138-0 · Cited by 830
Galili, U., Shohet, S. B., Kobrin, E., Stults, C. L., & Macher, B. A. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77900-9 · Cited by 817
Self-citation
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“In contrast to the genetic code, there are many more species-specific variations in glycans, ranging from entire classes of glycoconjugates, e.g., sulfated glycosaminoglycans not found in prokaryotes, to specific glycans, e.g., the absence of ɑ-Gal epitopes in old world monkeys (1051) , and the independent losses of t…”
BackgroundCetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Commins, S. P., Satinover, S. M., Hosen, J., Mozena, J., Borish, L., Lewis, B. D., Woodfolk, J. A., & Platts-Mills, T. A. E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.10.052 · Cited by 690
Commins, S. P., James, H. R., Kelly, L. A., Pochan, S. L., Workman, L. J., Perzanowski, M. S., Kocan, K. M., Fahy, J. V., Nganga, L. W., Ronmark, E., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.02.019 · Cited by 642
Vascular Tissue Engineering: Progress, Challenges, and Clinical Promise
Song, H.-H. G., Rumma, R. T., Ozaki, C. K., Edelman, E. R., & Chen, C. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.02.009 · Cited by 476
Metadata
- Authors
- Galili, U.
- Venue
- Immunology & Cell Biology
- Publisher
- Wiley
- Published
- 2005-10-21
- Volume
- 83
- Issue
- 6
- Pages
- 674-686
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- 1440-1711
- OpenAlex
- W2151173049
- Cited by
- 336
- References
- 125
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy. https://app.cochat.ai/papers/10.1111/j.1440-1711.2005.01366.x
- The paper
- Galili, U. (2005). The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy. Immunology & Cell Biology. https://doi.org/10.1111/j.1440-1711.2005.01366.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.